Glenmark launches Lobeglitazone in India

10 Oct 2022 , 09:34 PM

Glenmark Pharmaceuticals became the first to launch Thiazolidinedione Lobeglitazone Lobeglitazone in India for the treatment of type 2 diabetes in adults Marketed under the brand name LOBG; it contains Lobeglitazone 05 mg and to be taken once daily under prescription to improve glycemic control in adult diabetic patients Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin]resistant diabetic patients Glenmark earlier received approval from the Indian drug regulator Drug Controller General of India for manufacturing and marketing Lobeglitazone based on a randomized double]blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients aged 18 years and older The results of this trial have shown a faster and improved glycemic control with Lobeglitazone